Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth More Optimistic About Medicare Rx; Protonix May Benefit

Executive Summary

Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30

You may also be interested in...



Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List

Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL

Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List

Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL

No News Is Good News For Wyeth: Smooth Quarter Will Beat Expectations

A lack of "negative surprises" for Wyeth during the first quarter is contributing to financial results well above analyst estimates, the company said

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel